ADOCIA and Tonghua Dongbao Announce Positive Topline Results of Phase 3 Clinical Trial on Ultra-Rapid Insulin BioChaperone® Lispro (THDB0206 injection) in people with T1D

About this update from Tonghua Dongbao Pharmaceutical Co., Ltd. Class A

[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":3539,"height":1431,"url":"https://media.zenfs.com/en/business-wire.com/96ec4a336c43b25fa9ab430c4b42b444"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/ZDVlDHuqFK45lVEJKjDZ8g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTM4ODtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/96ec4a336c43b25fa9ab430c4b42b444","width":960,"height":388},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/miPDs2vay6FCFQNZws61Qg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD05NzA7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/96ec4a336c43b25fa9ab430c4b42b444","width":1200,"height":485}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"This Phase 3 clinical trial on BioChaperone® Lispro (THDB0206 injection) conducted in China in people with Type 1 Diabetes, successfully demonstrated, in comparison with standard of care Humalog®:","length":196,"tagName":"p","attribs":{}},{"type":"list","items":[{"val":[{"type":"text","content":"Non inferior HbA1c reduction at 26 weeks (primary endpoint)","length":59,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Significant reduction of the rise of blood glucose after a test meal (key secondary endpoint)","length":93,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":152,"olType":false}]},{"val":[{"type":"text","content":"Blood glucose level, monitored by 10-point self-monitoring blood glucose (SMBG), was statistically decreased 1 hour after each meal in comparison with Humalog®","length":159,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"These results complete and confirm the positive outcomes previously obtained with THDB0206 injection in people with Type 2 Diabetes","length":131,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":638,"olType":false},{"type":"text","content":"LYON, France, October 15, 2025--(BUSINESS WIRE)--Regulatory News:","length":65,"tagName":"p"},{"type":"text","content":"Adocia (Euronext Paris: FR0011184241 – ADOC, the "Company"), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and obesity, announces that its partner Tonghua Dongbao releases today posit...

More updates from Tonghua Dongbao Pharmaceutical Co., Ltd. Class A